权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting oncogenic pathways for chemoprevention of head and neck cancer by FLLL12

通过 FLLL12 靶向致癌途径对头颈癌进行化学预防

基本信息

批准号：
10497514
负责人：
A.R.M. Ruhul Amin
金额：
$ 44.4万
依托单位：
MARSHALL UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10497514
关键词：
AKT1 gene Affect Animal Model Award Binding Binding Sites Biological Assay Biological Markers Cancer Biology Cancer Model Cancer cell line Carcinogens Cell Culture Techniques Cell Death Cell Line Cell Survival Cell-Free System Cells Chemoprevention Chemopreventive Agent Curcumin Data Deletion Mutation Disease Drug Kinetics Drug Targeting EGFR inhibition Effectiveness Epidermal Growth Factor Receptor FRAP1 gene Faculty Future Genes Genetic Transcription Goals Grant Growth Head and Neck Squamous Cell Carcinoma Histologic Human In Vitro Incidence JAK2 gene Janus kinase Lesion Malignant Neoplasms Malignant Squamous Cell Neoplasm Measures Mediating Methods Modeling Molecular Morbidity - disease rate Mouth Neoplasms Mus Natural Compound Normal Cell Oncogenic Oral Outcome Pathway interactions Phosphorylation Inhibition Phosphotransferases Plasmids Premalignant Cell Prevention Process Promoter Regions Proto-Oncogene Proteins c-akt Regulation Reporter Research Resistance Risk Reduction Role STAT3 gene Signal Pathway Signal Transduction Signal Transduction Pathway Testing Tissues Tobacco Transcript Treatment Protocols Writing Xenograft Model analog cancer cell cancer chemoprevention cancer invasiveness carcinogenesis cell growth chemical carcinogen chemotherapeutic agent chromatin immunoprecipitation clinical development constitutive expression differential expression effective therapy experimental study graduate student head and neck cancer prevention improved in vivo interdisciplinary collaboration mRNA Expression malignant mouth neoplasm member meter mortality mouse model novel oral carcinogenesis overexpression pharmacologic preclinical development premalignant prevent promoter training opportunity transcription factor transcriptome sequencing tumor growth undergraduate student

项目摘要

PROJECT SUMMARY The delay or prevent the progression of premalignant lesions to invasive cancer by chemoprevention of squamous cell carcinoma of head and neck (SCCHN) is a devastating disease with significant morbidity and mortality. This research will investigate the use of FLLL12, a compound structurally related to the natural compound curcumin, as a novel compound for chemoprevention of this deadly cancer; FLLL12 demonstrates a cell signaling profile of binding to Janus kinase (JAK)2 and inhibition of the phosphorylation of STAT3. In addition, FLLL12 inhibits EGFR and AKT transcripts resulting in inhibition of EGFR/AKT-mTOR signaling. These signaling pathways confer cells with the ability to acquire the advantage of unlimited growth and resistance to cell death - two hallmarks of carcinogenesis. An effective chemoprevention method implemented before an invasive cancer develops is needed to reduce the incidence of SCCHN; however, currently no such treatment regimen is available. Thus, the identification of new compounds effective in preventing SCCHN carcinogenesis is warranted. In this proposal, we will develop FLLL12 as a therapeutic agent for the chemoprevention of SCCHN. Our preliminary data demonstrate that FLLL12 has IC50 values in a highly selective range (<1 µM against most SCCHN cell lines and 0.35 µM against a premalignant oral cancer cell line). Pharmacokinetic studies reveal that a pharmacologically relevant concentration is achievable in mice. FLLL12 also effectively inhibits tumor growth in a xenograft model of SCCHN. This proposal will test the ability of FLLL12 to prevent or delay the progression of premalignant lesions to SCCHN in a carcinogen-induced oral cancer model in a mouse model and uncover the cell signaling mechanism(s) of action for this agent. We hypothesize that FLLL12 regulates JAK-STAT3 and EGFR/AKT-mTOR survival pathways to reverse and/or slow the progression of premalignant lesions to a squamous cell cancer. Three specific aims are proposed. Aim 1: Evaluate the JAK-STAT3 pathway as a direct target of FLLL12. We will test the prediction that FLLL12 interacts with JAK2 and inhibits JAK-STAT3 pathway to mediate the chemoprevention effects of this compound. A cell free system, in vitro kinase assays, reporter assays and a constitutively active STAT3 plasmid will be used. Aim 2: Define the mechanism of regulation of the EGFR-AKT pathway by FLLL12. By employing promoter deletion-mutation, we will identify transcription factor(s) that inhibit EGFR and AKT transcripts. Aim 3: Analyze the in vivo efficacy of FLLL12 as a chemoprevention agent in a carcinogen-induced oral carcinogenesis model. A 4NQO-induced oral cancer mouse model will evaluate the prevention or delay in oral carcinogenesis with administration of FLLL12. The outcome of the in vivo studies will confirm the chemoprevention effects of FLLL12 in SCCHN. Importantly, this R15 award will provide a stimulating training opportunity for undergraduate and graduate students to participate actively in the research and discovery process to improve our understanding of the signal transduction pathways involved in cancer biology.

项目摘要通过化学预防来延迟或防止癌前病变向浸润性癌的进展，头颈部鳞状细胞癌（SCCHN）是一种具有显著发病率的毁灭性疾病， mortality.这项研究将调查FLLL 12的使用，FLLL 12是一种结构上与天然药物相关的化合物。化合物姜黄素，作为一种新的化合物，用于化学预防这种致命的癌症; FLLL 12表明，结合Janus激酶（JAK）2的细胞信号传导谱和抑制STAT 3的磷酸化。此外，本发明还提供了一种方法， FLLL 12抑制EGFR和AKT转录物，导致EGFR/AKT-mTOR信号传导的抑制。这些信令途径赋予细胞获得无限生长和抵抗细胞死亡的优势的能力，致癌的两个标志一种有效的化学预防方法在浸润性癌症之前实施降低SCCHN的发病率是必要的;然而，目前还没有这样的治疗方案， available.因此，鉴定新的化合物有效地防止SCCHN致癌是必要的。在这个提议中，我们将开发FLLL 12作为SCCHN化学预防的治疗剂。我们初步数据表明，FLLL 12的IC 50值在高度选择性范围内（对大多数药物<1 µM） SCCHN细胞系和0.35 µM针对癌前口腔癌细胞系）。药代动力学研究表明，在小鼠中可达到与药物浓度相关的浓度。FLLL 12还有效抑制肿瘤生长在SCCHN异种移植模型中。该提案将测试FLLL 12预防或延迟进展的能力在致癌物诱导的小鼠口腔癌模型中，该试剂的细胞信号传导机制。我们假设FLLL 12调节JAK-STAT 3， EGFR/AKT-mTOR生存通路逆转和/或减缓癌前病变进展至癌前病变鳞状细胞癌提出了三个具体目标。目的1：评估JAK-STAT 3通路作为直接的 FLLL 12的目标。我们将验证FLLL 12与JAK 2相互作用并抑制JAK-STAT 3通路的预测介导这种化合物的化学预防作用。无细胞系统，体外激酶测定，报告基因将使用组成型活性STAT 3质粒。目标2：确定监管机制， FLLL 12的EGFR-AKT通路。通过启动子缺失-突变，我们将鉴定转录因子，抑制EGFR和AKT转录物。目的3：分析FLLL 12作为化学预防剂的体内功效在致癌物诱导的口腔癌发生模型中。4 NQO诱导的口腔癌小鼠模型将评估通过施用FLLL 12预防或延迟口腔癌发生。体内研究的结果将证实了FLLL 12在SCCHN中的化学预防作用。重要的是，这个R15奖项将提供一个刺激的为本科生和研究生提供积极参与研究和发现的培训机会这一过程有助于提高我们对癌症生物学中信号转导途径的理解。